| Abeona Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Co.'s primary clinical program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, which is in the pivotal Phase 3 VIITAL clinical trial. Co. is developing additional adeno-associated virus (AAV)-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM capsid platform that Co. has licensed from University of North Carolina at Chapel Hill, and internal AAV vector research programs. We show 33 historical shares outstanding datapoints in our ABEO shares outstanding history coverage, used to compute ABEO market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ABEO market cap history over the course of time is important for investors
interested in comparing ABEO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ABEO versus a peer is one thing; comparing
ABEO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ABEO can fluctuate over the course of history.
With this page we aim to empower investors researching ABEO by allowing them to research the ABEO market cap history.